Xenon Pharmaceuticals Inc.

XENE

Held by 14 specialist biotech funds

High Convergence

14 funds opened new positions. Next phase2 readout (XPF-001): Nov 2009. Short interest: 4.3% of float.

BiotechnologyCEO: Andrea DiFabioIPO: 2014Website ↗

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Catalysts

Phase 2Q4 2009XPF-001Dental PainNCT00954356

Primary: Total Pain Relief at 6 Hours Post Dose (TOTPAR 6) (6 hours post dose)Enrollment:61/61Sites: 1RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q3 2010XPF-001Primary Erythromelalgia, Inherited ErythromelalgiaNCT01090622

Primary: Pain intensity difference (PID) in each treatment period based on an 11-point Pain Intensity-NRS (where 0 = No pain and 10 = worst pain you can imagine) (2 days)Enrollment:4/4Sites: 1RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q1 2011XPF-002Postherpetic NeuralgiaNCT01195636

Primary: Change in Mean Daily Pain Score From Baseline to Week 3 (With LOCF) (3 weeks)Enrollment:70/70Sites: 24RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q2 2012XPF-002Primary Erythromelalgia, Inherited ErythromelalgiaNCT01486446

Primary: Average Daily Use of Cooling for Erythromelalgia-Related Pain in Treatment Period 2 (14-21 Days)Enrollment:8/8Sites: 1RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2PositiveQ3 2021XEN1101Focal EpilepsyNCT03796962

Primary: Median Percent Change in Focal Seizure Frequency (From baseline (8 weeks prior to Day 0) through to the final dose (up to Day 56))Enrollment:325/325Sites: 95RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3NegativeQ2 2023XEN496Epilepsy, Epilepsy in Children, Epilepsy; SeizureNCT04639310

Phase 2Q3 2023XEN1101 10 mgMajor Depressive DisorderNCT05376150

Phase 3PositiveQ1 2026AzetukalnerFocal Onset SeizuresNCT05614063

Phase 3Q3 2026AzetukalnerMajor Depressive DisorderNCT06775379

PDUFAQ3 2026AzetukalnerFocal Onset Seizures

Phase 3Q4 2026XEN1101Focal Onset SeizuresNCT05716100

Phase 3Q1 2027AzetukalnerMajor Depressive DisorderNCT06922110

Phase 3Q2 2027XEN1101Primary Generalized Tonic-Clonic SeizuresNCT05667142

Phase 3Q2 2027AzetukalnerMajor Depressive DisorderNCT07076407

Phase 3Q2 2028AzetukalnerBipolar Disorder, Bipolar Depression, Bipolar I DisorderNCT07172516

Primary: Change from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score at Week 6. (Baseline to Week 6)Enrollment:Target 400Sites: 28RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q2 2029AzetukalnerBipolar Depression, Bipolar I Disorder, Bipolar DisorderNCT07217860

Phase 3Q2 2033XEN1101Focal Epilepsy, Tonic-Clonic SeizuresNCT05718817

Xenon Pharmaceuticals Inc.

Signal Score

Conviction + Catalyst

Fund Holdings

Position Trend

Short Interest

Catalysts

Activist Filings

Position Details

Know which insider moves are real

Insider Signals

Also Held by These Funds

Research Links

Related Research